Anumana Welcomes Dr. Simos Kedikoglou as New COO
Related Articles
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening diseaseMay 23, 2022
Anumana Expands AI Platform from Diagnostic Solutions to the Full Continuum of Cardiovascular Care
New investment fuels growth of ECG-AI platform and development of perioperative AI capabilitiesApril 24, 2025
Way of Diagnosing PH in Common Heart Test Gets FDA Support
Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The…May 26, 2022
AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Healio: Anumana announced it received FDA breakthrough device designation for its artificial intelligence-guided ECG algorithm for the early identification of cardiac amyloidosis.June 21, 2023